HFA Premium Access

Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results

Congress Presentation

About the speaker

Associate Professor Leo Niskanen

Helsinki University Central Hospital, Helsinki (Finland)
0 follower

8 more presentations in this session

Testing for iron deficiency and use of ferric carboxymaltose in patients with heart failure: need for implementation? data from the swedish heart failure registry

Speaker: Doctor P. Becher (Hamburg, DE)

Thumbnail

Disparities in follow-up rates after heart failure hospitalisation decreased during the COVID-19 pandemic

Speaker: Doctor Z. Hughes (Chicago, US)

Thumbnail

Different renal function patterns in patients with acute heart failure: relationship with outcome and congestion

Speaker: Associate Professor A. Palazzuoli (Siena, IT)

Thumbnail

Readmissions in heart failure patients: a portuguese administrative database study from 2008 to 2017

Speaker: Mrs M. Pardal (Lisboa, PT)

Thumbnail

No change in predicted risk for in-hospital and one-year mortality in patients hospitalised with heart failure during as compared to before the COVID-19 pandemic

Speaker: Doctor J. Simkowski (Chicago, US)

Thumbnail

Access the full session

Acute Heart Failure - Epidemiology, Prognosis, Outcome

Speakers: Associate Professor L. Niskanen, Doctor P. Becher, Doctor Z. Hughes, Associate Professor A. Palazzuoli, Mrs M. Pardal...
Thumbnail

About the event

Image

Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations